Introduction
Quibim is a Valencia-based medical imaging company founded in 2015 that applies artificial intelligence to MRI, CT, and PET quantitative biomarkers for hospitals and life sciences. Dr. Ángel Alberich-Bayarri co-founded Quibim and serves as chief executive officer per the company team page reviewed in July 2026. QUantitative Imaging Biomarkers In Medicine — the acronym behind the name — reflects a research-heavy origin commercialized internationally from 2021 with SaaS hospital products and value-based life sciences partnerships.
On July 2, 2026, Quibim announced the European and UK launch of QP-Breast, described as the first CE and UKCA-marked AI tool in Europe and the United Kingdom to detect breast cancer using magnetic resonance imaging — automatically identifying suspected lesions and generating structured reports integrated into hospital systems.
What the company does
QP-Breast assists radiologists during breast MRI interpretation by highlighting suspicious regions, reporting lesion size, volume, location, and malignancy likelihood estimates grounded in biopsy-confirmed training data per the July 2026 release. The product targets both screening and diagnostic MRI for high-risk women and dense-breast populations where MRI demand rises faster than radiologist staffing. QP-Prostate — CE, UKCA, and FDA 510(k) cleared — remains the flagship cited for detecting up to 90% of prostate cancer cases in company materials, establishing regulatory credibility QP-Breast extends into breast oncology.
Quibim’s platform markets predictive imaging biomarker panels to life sciences for oncology, immunology, and neurology trials — dual hospital SaaS and pharma partnership revenue streams Alberich-Bayarri references when quoting radiology workload relief alongside patient care improvement.
Who it serves
Quibim serves hospital radiology departments, breast MRI screening programs, specialist imaging centers, and pharmaceutical sponsors needing quantitative imaging endpoints. The July 2026 release cites more than 470 sites using Quibim products globally — a deployment scale metric enterprise buyers request before multi-site MRI AI rollouts. Offices span New York, Dallas, Cambridge, Valencia, Madrid, and Barcelona per the announcement, reflecting U.S. and UK commercialization alongside European launches.
Alberich-Bayarri’s quoted emphasis on automating time-consuming MRI analysis while preserving clinician decision authority matches regulatory Class IIb EU MDR and UK Class IIa framings described for QP-Breast — decision-support positioning radiology legal teams prefer over autonomous diagnosis claims.
Company background
Alberich-Bayarri founded Quibim in 2015 after years of imaging biomarker research, leading commercial internationalization in 2021 as team and product lines expanded. The team page lists chief operating, commercial, business, people, quality, and technology officers — leadership depth typical of multi-market medical device software vendors pursuing U.S., EU, and UK clearance simultaneously. Quibim’s about page states ambition to transform healthcare through AI-guided precision solutions unlocking imaging data for outcomes.
Product and AI capabilities
QP-Breast integrates directly into hospital systems without workflow disruption per the launch release — a technical requirement for breast MRI programs already juggling BI-RADS reporting, biopsy coordination, and multidisciplinary tumor boards. Quibim cites BI-RADS v2025 manual context for biopsy statistics noting up to four of five biopsied lesions may be benign — the false-biopsy burden MRI AI must reduce to prove economic value beyond sensitivity alone.
Life sciences biomarker panels and regulatory-cleared devices share underlying segmentation and quantification engines — Quibim’s research publications and multi-product newsroom cadence in 2026 illustrate parallel hospital and trial monetization.
Key developments
2015: Quibim founded in Valencia by Angel Alberich-Bayarri. 2021: Commercial internationalization phase per about page. July 2, 2026: QP-Breast CE and UKCA launch across Europe and UK (official source). 2026 newsroom: QP-Prostate Health Canada licence and New York strategic AI program selection posts on quibim.ai.
Why it matters
Quibim matters because breast MRI AI lacked CE and UKCA-marked detection tools in Europe before QP-Breast — filling a regulatory gap as MRI screening expands for high-risk cohorts. Alberich-Bayarri’s prostate MRI track record gives hospitals a vendor with multi-organ regulatory experience rather than first-product startups. Compare with Niramai radiation-free thermal screening and Idoven cardiovascular AI — Quibim owns MRI oncology quantification at payer-sensitive price points.
Sector context
Quibim belongs in Brel’s AI in healthcare coverage under medical imaging and MRI AI oncology. Distinct from chest CT lung vendors in this batch — breast MRI AI competes on biopsy yield reduction and radiologist reading time per case. Verify MDR Class IIb and UKCA documentation during hospital vendor qualification; life sciences buyers should separate trial biomarker SaaS from cleared device modules.
Sources and references
Quibim QP-Breast launch newsroom article (July 2, 2026) and team page with Angel Alberich-Bayarri.
- Quibim — QP-Breast CE UKCA launch (quibim.ai, July 2, 2026)
- Quibim — Team / leadership (quibim.ai)
Reviewed July 10, 2026. Angel Alberich-Bayarri is CEO and co-founder. quibim.com redirects to quibim.ai. Confidence: High.